Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.

PMID: 30227064 · 2016

JournalTherapeutic innovation & regulatory science
Year2016
PMID30227064

Abstract

The US Food and Drug Administration (FDA) is responsible for protecting public health. Issuance of a warning letter is the FDA's principal means of achieving prompt voluntary compliance with regulations. The objective of this study is to analyze the trends of warning letters issued to medical products about current good manufacturing practices (CGMP) violations during 2007-2014, with a secondary purpose of providing suggestions to manufacturers on how to avoid warning letters. Warning letters we

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.